Article ; Online: Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
2020 Volume 20, Issue 1, Page(s) 91–101
Abstract: Background: This systematic review and meta-analysis was conducted to evaluate the safety and effectiveness of Atazanavir/ritonavir over lopinavir/ritonavir in human immunodeficiency virus-1 (HIV-1) infection.: Methods: Clinical trials with a head-to- ...
Abstract | Background: This systematic review and meta-analysis was conducted to evaluate the safety and effectiveness of Atazanavir/ritonavir over lopinavir/ritonavir in human immunodeficiency virus-1 (HIV-1) infection. Methods: Clinical trials with a head-to-head comparison of atazanavir/ritonavir and lopinavir/ritonavir in HIV-1 were included. Electronic databases: PubMed/Medline CENTRAL, Embase, Scopus, and Web of Science were searched. Viral suppression below 50 copies/ml at the longest follow-up period was the primary outcome measure. Grade 2-4 treatment-related adverse drug events, lipid profile changes and grade 3-4 bilirubin elevations were used as secondary outcome measures. Results: A total of nine articles from seven trials with 1938 HIV-1 patients were included in the current study. Atazanavir/ritonavir has 13% lower overall risk of failure to suppress the virus level < 50 copies/ml than lopinavir/ritonavir in fixed effect model (pooled RR: 0.87; CI: 0.78, 0.96; P=0.006). The overall risk of hyperbilirubinemia is very high for atazanavir/ritonavir than lopinavir/ritonavir in the random effects model (pooled RR: 45.03; CI: 16.03, 126.47; P< 0.0001). Conclusion: Atazanavir/ritonavir has a better viral suppression at lower risk of lipid abnormality than lopinavir/ritonavir. The risk and development of hyperbilirubinemia from atazanavir-based regimens should be taken into consideration both at the time of prescribing and patient follow-up. |
---|---|
MeSH term(s) | Antiretroviral Therapy, Highly Active/adverse effects ; Antiretroviral Therapy, Highly Active/methods ; Atazanavir Sulfate/pharmacology ; Atazanavir Sulfate/therapeutic use ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV Protease Inhibitors/pharmacology ; HIV Protease Inhibitors/therapeutic use ; HIV-1/drug effects ; Humans ; Hyperbilirubinemia/chemically induced ; Lopinavir/pharmacology ; Lopinavir/therapeutic use ; Ritonavir/adverse effects ; Treatment Outcome ; Viral Load |
Chemical Substances | HIV Protease Inhibitors ; Lopinavir (2494G1JF75) ; Atazanavir Sulfate (4MT4VIE29P) ; Ritonavir (O3J8G9O825) |
Language | English |
Publishing date | 2020-12-15 |
Publishing country | Uganda |
Document type | Journal Article ; Meta-Analysis ; Systematic Review |
ZDB-ID | 2240308-5 |
ISSN | 1729-0503 ; 1680-6905 |
ISSN (online) | 1729-0503 |
ISSN | 1680-6905 |
DOI | 10.4314/ahs.v20i1.14 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3851: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.